Artara Therapeutics Inc (TARA)

Jun 2, 2025, 4:04 PM EDT - 4 days ago

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

May 13, 2025, 8:00 AM EDT - 24 days ago

Protara Therapeutics to Participate in Upcoming Investor Conferences

May 8, 2025, 8:00 AM EDT - 4 weeks ago

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:09 PM EDT - 5 weeks ago

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 26, 2025, 10:00 AM EDT - 5 weeks ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Apr 23, 2025, 8:00 AM EDT - 6 weeks ago

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Apr 15, 2025, 4:13 PM EDT - 7 weeks ago

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Apr 10, 2025, 4:05 PM EDT - 2 months ago

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Mar 28, 2025, 5:10 PM EDT - 2 months ago

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Mar 19, 2025, 8:00 AM EDT - 2 months ago

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Mar 5, 2025, 8:00 AM EST - 3 months ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 26, 2025, 8:00 AM EST - 3 months ago

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Jan 13, 2025, 8:00 AM EST - 5 months ago

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Dec 14, 2024, 8:30 AM EST - 6 months ago

Protara Therapeutics: Rising From The Ashes

Dec 11, 2024, 4:05 PM EST - 6 months ago

Protara Announces Closing of $100 Million Public Offering

Dec 10, 2024, 5:00 PM EST - 6 months ago

Protara Therapeutics: Carving New Roads In Bladder Cancer

Dec 10, 2024, 3:55 PM EST - 6 months ago

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Dec 9, 2024, 11:35 PM EST - 6 months ago

Protara Announces Pricing of $100 Million Public Offering

Dec 9, 2024, 4:01 PM EST - 6 months ago

Protara Announces Proposed Public Offering

Dec 5, 2024, 10:50 AM EST - 6 months ago

Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

Nov 15, 2024, 5:52 PM EST - 7 months ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Nov 6, 2024, 8:00 AM EST - 7 months ago

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 21, 2024, 8:00 AM EDT - 8 months ago

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Sep 9, 2024, 8:05 AM EDT - 9 months ago

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Sep 9, 2024, 8:00 AM EDT - 9 months ago

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Sep 3, 2024, 8:00 AM EDT - 9 months ago

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Jun 24, 2024, 5:06 PM EDT - 1 year ago

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 21, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

May 2, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

Apr 5, 2024, 8:04 AM EDT - 1 year ago

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Apr 5, 2024, 8:02 AM EDT - 1 year ago

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Apr 5, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 8:00 AM EST - 1 year ago

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 22, 2024, 8:55 AM EST - 1 year ago

Protara: A Bombed Out Biotech With A Very Positive Skew

CGON

Nov 30, 2023, 8:30 AM EST - 1 year ago

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Nov 3, 2023, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Sep 20, 2023, 8:30 AM EDT - 1 year ago

Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

Sep 5, 2023, 7:30 AM EDT - 1 year ago

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

May 4, 2023, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update

May 2, 2023, 8:00 AM EDT - 2 years ago

Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development

Mar 8, 2023, 8:00 AM EST - 2 years ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 2, 2023, 8:00 AM EST - 2 years ago

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

Jan 30, 2023, 8:00 AM EST - 2 years ago

Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

Dec 1, 2022, 8:00 AM EST - 2 years ago

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

Nov 3, 2022, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview

Sep 6, 2022, 8:00 AM EDT - 2 years ago

Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference